收费全文 | 23034篇 |
免费 | 3557篇 |
国内免费 | 135篇 |
耳鼻咽喉 | 231篇 |
儿科学 | 495篇 |
妇产科学 | 605篇 |
基础医学 | 1993篇 |
口腔科学 | 613篇 |
临床医学 | 4769篇 |
内科学 | 4878篇 |
皮肤病学 | 432篇 |
神经病学 | 2607篇 |
特种医学 | 866篇 |
外科学 | 3711篇 |
综合类 | 71篇 |
一般理论 | 6篇 |
预防医学 | 2219篇 |
眼科学 | 701篇 |
药学 | 963篇 |
中国医学 | 33篇 |
肿瘤学 | 1533篇 |
2023年 | 652篇 |
2022年 | 200篇 |
2021年 | 657篇 |
2020年 | 736篇 |
2019年 | 582篇 |
2018年 | 1145篇 |
2017年 | 1105篇 |
2016年 | 1126篇 |
2015年 | 1137篇 |
2014年 | 1420篇 |
2013年 | 1608篇 |
2012年 | 1611篇 |
2011年 | 1590篇 |
2010年 | 1178篇 |
2009年 | 1216篇 |
2008年 | 1274篇 |
2007年 | 1170篇 |
2006年 | 1064篇 |
2005年 | 1045篇 |
2004年 | 875篇 |
2003年 | 748篇 |
2002年 | 702篇 |
2001年 | 281篇 |
2000年 | 147篇 |
1999年 | 257篇 |
1998年 | 355篇 |
1997年 | 296篇 |
1996年 | 368篇 |
1995年 | 269篇 |
1994年 | 260篇 |
1993年 | 215篇 |
1992年 | 175篇 |
1991年 | 152篇 |
1990年 | 97篇 |
1989年 | 114篇 |
1988年 | 97篇 |
1987年 | 85篇 |
1986年 | 84篇 |
1985年 | 69篇 |
1984年 | 60篇 |
1983年 | 56篇 |
1982年 | 48篇 |
1981年 | 36篇 |
1980年 | 29篇 |
1979年 | 28篇 |
1978年 | 22篇 |
1972年 | 21篇 |
1971年 | 36篇 |
1970年 | 23篇 |
1968年 | 25篇 |
Background
Advanced low-grade ovarian carcinoma (LGOC) is difficult to treat. In several studies, high estrogen receptor (ER) protein expression was observed in patients with LGOC, which suggests that antihormonal therapy (AHT) is a treatment option. However, only a subgroup of patients respond to AHT, and this response cannot be adequately predicted by currently used immunohistochemistry (IHC). A possible explanation is that IHC only takes the ligand, but not the activity, of the whole signal transduction pathway (STP) into account. Therefore, in this study, the authors assessed whether functional STP activity can be an alternative tool to predict response to AHT in LGOC.Methods
Tumor tissue samples were obtained from patients with primary or recurrent LGOC who subsequently received AHT. Histoscores of ER and progesterone receptor (PR) were determined. In addition, STP activity of the ER STP and of six other STPs known to play a role in ovarian cancer was assessed and compared with the STP activity of healthy postmenopausal fallopian tube epithelium.Results
Patients who had normal ER STP activity had a progression-free survival (PFS) of 16.1 months. This was significantly shorter in patients who had low and very high ER STP activity, with a median PFS of 6.0 and 2.1 months, respectively (p < .001). Unlike ER histoscores, PR histoscores were strongly correlated to the ER STP activity and thus to PFS.Conclusions
Aberrant low and very high functional ER STP activity and low PR histoscores in patients with LGOC indicate decreased response to AHT. ER IHC is not representative of functional ER STP activity and is not related to PFS. 相似文献Background
Limited data exist on the clinical behavior of pediatric non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) with distant metastases at onset, and a clear standard of care has not yet been defined.Methods
This cohort study reports on pediatric adult-type metastatic NRSTS enrolled in two concurrent prospective European studies, i.e., the randomized BERNIE study and the single-arm MTS 2008 study developed by the European paediatric Soft tissue sarcoma Study Group. Treatment programs were originally designed for patients with metastatic rhabdomyosarcoma, i.e., nine courses of multidrug chemotherapy (with or without bevacizumab in the BERNIE study), followed by 12 cycles of maintenance therapy, whereas radiotherapy and/or surgery (on primary tumor and/or metastases) were delayed until after seven courses of chemotherapy had been administered.Results
The study included 61 patients <21 years old treated from July 2008 to December 2016. The lung was the site of metastases in 75% of the cases. All patients received multi-agent chemotherapy, 44% had local therapy to primary tumor, and 18% had treatment of metastases. Median time to progression/relapse was 6 months. A high rate of tumor progression was observed during the initial part of the chemotherapy program. With a median follow-up of 41.5 months (range, 2–111 months), 3-year event-free survival and overall survival were 15.4% (95% confidence interval [CI], 7.6–25.7) and 34.9% (95% CI, 22.7–47.5), respectively. There were no statistically significant differences in outcome depending on the type of treatment administered.Conclusions
The study confirmed the overall poor outcome for patients with metastatic NRSTS, whose treatment remains a challenge.Plain Language Summary
- Pediatric non-rhabdomyosarcoma soft tissue sarcomas form a heterogeneous group of rare tumors.
- Although recent international studies have defined the standard of care for patients with localized disease, limited data are available on the clinical behavior of patients with distant metastases.
- This study on 61 metastatic cases treated on two prospective European protocols confirms that the chances of survival of such patients are often dismal and a standard treatment is still lacking.
We recently showed PAM50 gene expression data can be represented by five quantitative, orthogonal, multi-gene breast tumor traits. These novel tumor ‘dimensions’ were superior to categorical intrinsic subtypes for clustering in high-risk breast cancer pedigrees, indicating potential to represent underlying genetic susceptibilities and biological pathways. Here we explore the prognostic and predictive utility of these dimensions in a sub-study of GEICAM/9906, a Phase III randomized prospective clinical trial of paclitaxel in breast cancer.
MethodsTumor dimensions, PC1–PC5, were calculated using pre-defined coefficients. Univariable and multivariable Cox proportional hazards (PH) models for disease-free survival (DFS) were used to identify associations between quantitative dimensions and prognosis or response to the addition of paclitaxel. Results were illustrated using Kaplan–Meier curves.
ResultsDimensions PC1 and PC5 were associated with DFS (Cox PH p = 6.7 \(\times\) 10−7 and p = 0.036), remaining significant after correction for standard clinical–pathological prognostic characteristics. Both dimensions were selected in the optimal multivariable model, together with nodal status and tumor size (Cox PH p = 1.4 \(\times\) 10−12). Interactions with treatment were identified for PC3 and PC4. Response to paclitaxel was restricted to tumors with low PC3 and PC4 (log-rank p = 0.0021). Women with tumors high for PC3 or PC4 showed no survival advantage.
ConclusionsOur proof-of-concept application of quantitative dimensions illustrated novel findings and clinical utility beyond standard clinical–pathological characteristics and categorical intrinsic subtypes for prognosis and predicting chemotherapy response. Consideration of expression data as quantitative tumor dimensions offers new potential to identify clinically important patient subsets in clinical trials and advance precision medicine.
相似文献